Original Article
The impact of Xuebijing injection on postoperative inflammatory response and liver function in patients who underwent liver resection for hepatocellular carcinoma
Haorong Xie, Kai Wang, Jie Zhou
Published 2018-11-28
Cite as Chin J Hepatobiliary Surg, 2018, 24(11): 733-736. DOI: 10.3760/cma.j.issn.1007-8118.2018.11.002
Abstract
ObjectiveThis study aimed to investigate the impact of Xuebijing injection on postoperative inflammatory response and liver function in patients who underwent liver resection for hepatocellular carcinoma, and to evaluate its safety and clinical value.
MethodsThe clinical data of 426 HCC patients who underwent partial hepatectomy at the Nanfang Hospital, Southern Medical University from January 2015 to June 2017 were retrospectively studied. These patients were divided into the treatment group and the control group based on whether they were treated with Xuebijing injection or not. After propensity score matching, each group included 101 patients. The preoperative and postoperative WBC, NE%, C-reactive protein (CRP), body temperature, ALT, AST and TBil levels, as well as the occurrence of adverse drug reactions and the days and costs of hospitalization were compared between the two groups.
ResultsThere were no significant differences in ALT, AST, TBil, WBC, NE% before surgery between the two groups (P>0.05). When compared with the control group, the WBC, NE%, and CRP in the treatment group were significantly lower than those in the control group on day 3 and 5 after surgery: (11.5±3.2)×109/L vs (10.2±4.0)×109/L, (8.1±2.4)×109/L vs (7.3±2.8)×109/L; ( 78.3±11.6)% vs (73.3±6.4)%, (69.3±12.1)% vs (64.7±7.7)%; (81.2±51.8) mg/L vs (64.2±43.7) mg/L, (51.9±26.3) mg/L vs (44.4±24.0) mg/L, respectively. The differences were significantly difference (P<0.05). There were 76 patients with fever in the control group within 5 days after operation, and 60 patients in the treatment group, 75.2% vs 59.4%. The difference was significantly difference (P<0.05). The WBC, NE% of the two groups showed a gradual decline after surgery. The levels of ALT, AST and TBil on day 1, 3, 5 after operation were not significantly different between the two groups (all P>0.05). The total incidence of adverse drug reactions, postoperative hospital stay and hospitalization costs were not significantly different between the two groups (all P>0.05).
ConclusionXuebijing injection showed a good anti-inflammatory effect with no obvious liver toxicity in patients who underwent liver resection. It demonstrated good safety and could be applied to prevent and treat patients with excessive inflammatory reaction after liver resection.
Key words:
Xuebijing injection; Hepatectomy; Inflammatory response; Liver function
Contributor Information
Haorong Xie
Department of Hepatobiliary Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
Kai Wang
Jie Zhou
